Real-World Data
Move further and faster with the industry’s most comprehensive RWD solutions
Understanding Real-World Data
Data sources exist, however, significant challenges are associated with complicated accessibility, data interoperability, data quality and cumbersome harmonization. Furthermore, the most valuable data elements needed for comparative outcome studies are unstructured – e.g. captured in EHR case notes, driving variability and complexity exponentially.
Knowing Use-case (what will the data be used for), therapy area (patient and treatment journey, specific data elements, structured/unstructured EHR data, etc.) and geographic scope (local regulation, clinical guideline variations, etc.), time-line and budget available will enable the fit-for purpose RWD solution:
- Right Data sources: EMR, Registry, Patient Reported/Generated
- Data collection & Tech: Primary data collection via eCRF, Secondary data collection via federation and/or existing databases, combination
- Right solution: Interventional Study, Observational study
Rich Real-World Datasets and Know-How at Your Fingertips
Strong Footprint
United States
United Kingdom
European Union
Japan
Five Specialized Fields
Oncology
Cardiology
Neurology
Hematology
Rare Diseases
We offer the industry’s most Comprehensive Real-World Data Solutions
Take advantage of our expertise and global footprint to diversify your data sources and add rapidly a wider global reach to your studies. We do the heavy lifting for you.
Oncology Real-World Data
Discover our extensive experience in Oncology Real-World Data for Life Sciences
Real-World Data (RWD) plays a crucial role in oncology research and drug development by providing a more comprehensive, real-world perspective on how treatments work, their effectiveness in diverse patient populations, and their long-term safety and cost-effectiveness. However, to accurately reflect the real world, RWD must be sufficiently powered, and of requisite quality, requiring large patient numbers from diverse geographic areas to accurately reflect each region.
BC Platforms facilitates access to such data in a transparent manner, with longstanding expertise in health data management and secure research collaborations.
-
BC Platforms has established trust-based relationships with notable cancer-related institutions and key opinion leaders. It brings together stakeholders and understands the regulation authority, the buyers, the researchers, and the patients and caregivers – critical knowledge and experience when working with RWD.
BC Platforms’ Contributions to current Cancer Research initiatives:
CIAN Lung
BC Platforms promotes CIAN —”Cohort Insights Analytics Networks”— providing “ready to use” tailored datasets for exploratory and descriptive analyses. This comprehensive approach integrates medical images, clinical, biological, histological, and molecular data, reflecting our commitment to advancing healthcare through innovative data solutions.
CIAN Lung is a multimodal cohort of Lung Cancer patients for clinical research and RWE projects
-
- Multimodal approach including pathology, biology, imaging, radiotherapy, clinical data, and genomics.
- Harmonized data model used by data partners ensuring high-quality data.
- Clinical use cases sponsored by academics, biotech, top pharmaceutical, and medical device companies.
- Continuously evolving cohort in NSCLC and SCLC for the development of new solutions for patients.
Explore Our Global Data Network
Informed Innovation
Take an in-depth look at solutions delivered by BC Platforms, stay informed with the latest industry news, and more.
Transforming Oncology through Real-World Data
Using Real-World Data as External Control Arm (ECA)
